uniQure N.V. (QURE) earnings date
Mar 1, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | before open | 35 | 8-K |
| Q2 FY2026 | Wed, Jul 29, 2026 | before open | 29 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | before open | 35 | 8-K |
| Q4 FY2025 | Mon, Mar 2, 2026 | before open | 61 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | before open | 41 | 8-K |
| Q2 FY2025 | Tue, Jul 29, 2025 | before open | 29 | 8-K |
| Q1 FY2025 | Fri, May 9, 2025 | before open | 39 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening expected to begin by end of 2026 ~" exhibit |
| Q3 FY2026 | "~ Cash, cash equivalents and investment securities of approximately $768.4 million as of September 30, 2026 expected to fund operations into 2030 ~" exhibit |
| Q3 FY2026 | "· In the third quarter of 2026, the Company completed enrollment in the second dose cohort of seven patients in the ongoing Phase I/IIa study and expects to present updated results in the first half of 2027." exhibit |
| Q3 FY2026 | "· The Company expects to present updated results from the Phase I/II study in all dosing cohorts in the first half of 2027." exhibit |
| Q3 FY2026 | "The Company expects that these resources will be sufficient to fund projected operating expenses into 2030." exhibit |
| Q2 FY2026 | "EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy showed early biological signals of therapeutic activity and a favorable safety profile ~ ~ Strengthened financial positio" exhibit |
| Q2 FY2026 | "“Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter — a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease." exhibit |
| Q2 FY2026 | "With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it.”" exhibit |
| Q2 FY2026 | "Discussions with the FDA to align on the confirmatory study design and analysis are underway and the Company expects to submit a BLA in the third quarter of 2026." exhibit |
| Q2 FY2026 | "The Company expects to complete enrollment in the second dose cohort in the Phase I/IIa study in the third quarter of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/QURE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/QURE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/QURE/"><img src="https://veritasdata.dev/embed/QURE.svg" alt="QURE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/QURE/)
Script
<script async src="https://veritasdata.dev/embed/QURE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/QURE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.